UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): ~~December~~January 15, ~~2025~~2026

OraSure Technologies, Inc.

(Exact Name of Registrant as Specified in Charter)


Delaware	001-16537	36-4370966
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)


220 East First Street Bethlehem, Pennsylvania			18015-1360
(Address of Principal Executive Offices)			(Zip Code)

Registrant’s telephone number, including area code: 610-882-1820

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

Common Stock, $0.000001 par value per share

OSUR

The Nasdaq Stock Market LLC

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by a check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 87.01 - ~~Other~~Regulation ~~Events~~FD Disclosure

On ~~December~~January 15, ~~2025~~2026, OraSure Technologies, Inc. (the “Company”) ~~reported~~announced that ~~each~~it ofhas ~~Carrie~~submitted ~~Eglinton~~two ~~Manner, President, Chief Executive Officer and Director, and Kenneth McGrath, Chief Financial Officer, adopted~~ separate ~~Rule~~applications ~~10b5-1~~to ~~trading plans for purchases of~~ the ~~Company’s common stock~~U.S. AsFood aand ~~result~~Drug ofAdministration ~~the~~(“FDA”) ~~Company’s~~for ~~ongoing~~clearance ~~share repurchase program, purchases are subject to the parameters~~ of ~~the~~its ~~Rule~~rapid ~~10b5-1~~molecular ~~trading plans, which were adopted in accordance with Rule 10b5~~self-1test ~~under~~for ~~the~~Chlamydia ~~Securities~~Trachomatis ~~Exchange~~and ~~Act~~Neisseria ofGonorrhoeae ~~1934,~~(“CT/NG”) ~~as amended,~~ and ~~the~~its ~~Company’s~~Colli-Pee™ ~~Insider Trading Policy and~~ at-home aurine ~~time~~collection ~~when~~device, ~~the~~including ~~applicable~~for ~~officer~~sexually ortransmitted ~~director~~infections ~~was not aware of material nonpublic information~~(“STIs”).

~~Under~~The information in Item 7.01 and attached as Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the ~~terms~~Securities Exchange Act of 1934 or otherwise subject to the ~~respective~~liabilities ~~Rule~~of ~~10b5~~that section, nor shall such information and Exhibit be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such a filing. The fact that the information and Exhibit are being furnished should not be deemed an admission as to the materiality of any information contained therein. The Company undertakes no duty or obligation to publicly update or revise the information contained in this Current Report on Form 8-1K ~~trading~~or ~~plans:~~the attached Exhibit.

~~•Ms~~Item 8.01 ~~Eglinton~~Other ~~Manner has the potential to purchase up to $165,000 of shares of the Company’s common stock over a term ending six months after the Commencement Date (as defined below)~~Events.

~~•Mr.~~The ~~McGrath~~Company ~~has~~submitted ~~the~~applications ~~potential~~ to ~~purchase~~the upFDA tofor ~~$165,000~~clearance offor ~~shares~~each of ~~the~~its rapid molecular self-test for CT/NG and its Colli-Pee at-home urine collection device for STIs. The Company’s ~~common~~rapid ~~stock~~molecular ~~over~~self-test for CT/NG is designed to provide results in approximately 30 minutes in a ~~term~~disposable ~~ending~~format ~~six~~that ~~months~~is ~~after~~intended for over-the-counter ~~Commencement~~usage. ~~Date~~The Colli-Pee device is designed for at-home urine collection, including for multiple STI indications.

~~Trading~~Item ~~under~~9.01 ~~each plan will begin only after the applicable Rule 10b5~~-1 ~~cooling~~Financial ~~off~~Statements ~~period (i.e., the later of 90 days from adoption~~ and two business days after the filing of the Company’s Annual Report on Form 10 K, but not to exceed 120 days (the “Commencement Date”)), and each plan includes the required good faith certificationsExhibits.

~~Under~~(d) the terms of the Rule 10b5-1 trading plans, each of Ms. Eglinton Manner and Mr. McGrath will have no discretion or control over the timing or effectuation of any transactions in Company securities pursuant to their respective plans. Transactions under the plans, if any, will be reported in accordance with Section 16 of the Securities Exchange Act of 1934, as amended.Exhibits



Exhibit Number						Description

99.1						Press Release of OraSure Technologies, Inc., dated January 5, 2026
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ORASURE TECHNOLOGIES, INC.
Date: December 1, 2025	By:	/s/ Carrie Eglinton Manner
Date: January 5, 2026	By:	/s/ Carrie Eglinton Manner
		Carrie Eglinton Manner
		President and Chief Executive Officer

Filing Compare · ORASURE TECHNOLOGIES INC